Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Comment by SizzlinSteakson Dec 28, 2017 5:34pm
209 Views
Post# 27241135

RE:Hi all

RE:Hi allKALY is a nice little mix. She is in the hottest space right now (cannabis) and pharmaceutical which can be explosive at the right stages (currently phase 2). It is also nice that she is in a unique space "one of a kind sorta speak" and is working on numberous targets. Top that off with the fact she is working with a billion dollar company (Salzman Group) who is partially funding the study and taking payment in the form of shares. If you ask me she is looking darn HOT. 
Looking around at the other cannabis plays, it is quite possible we could see a new valuation in excess of 100 million in short order and quite possibly hundreds of millions in the months to come.

All just my opinion of course and we have to consider there are always many factors at play that can affect valuation one way or another but for now I would say things are looking UP.

acctguy wrote: haha, JohnJameson115, I saw your calls, you deserve some cred.

I just jumped into Kaly, exciting finish, bought in an hour before closing and then doubled up my holding right at end, so definitely hoping for a morning gap up.

I am a long holder by nature.

Wondering where people see this stock in the future for longs

Thanks all.


Bullboard Posts